CAR-γδ T(Ansun Biopharma)(CAR-γδ T(Ansun Biopharma)) - 在研适应症：实体瘤_专利_临床

概要

基本信息

药物类型

CAR-T

别名-

靶点-

作用机制-

治疗领域

肿瘤

在研适应症

实体瘤

非在研适应症-

原研机构

Ansun Biopharma, Inc.

在研机构

Ansun Biopharma, Inc.

非在研机构-

最高研发阶段药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 CAR-γδ T(Ansun Biopharma) 相关的临床结果

登录后查看更多信息

100 项与 CAR-γδ T(Ansun Biopharma) 相关的转化医学

登录后查看更多信息

100 项与 CAR-γδ T(Ansun Biopharma) 相关的专利（医药）

登录后查看更多信息

1

项与 CAR-γδ T(Ansun Biopharma) 相关的文献（医药）

Medical Oncology

Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors

Review

作者: Zeng, Xun ; Ye, Mengke ; Zhang, Yixi ; Yuan, Guangxun

Chimeric Antigen Receptor T cell (CAR-T) therapy has revolutionized cancer treatment, but its application to solid tumors is limited. CAR-T cells have poor incapability of entering, surviving, proliferating, and finally exerting function in the tumor microenvironment. This review summarizes the main strategies related to enhancing the infiltration, efficacy, antigen recognition, and production of CAR-T in solid tumors. Additional applications of CAR-γδ T and macrophages are also discussed. We believe CAR-T will be a milestone in treating solid tumors once these problems are solved.

100 项与 CAR-γδ T(Ansun Biopharma) 相关的药物交易

登录后查看更多信息